Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation.
Bronchodilators
COVID-19
Chronic disease
Disability
Outcome
Rehabilitation
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
07
03
2021
revised:
05
04
2021
accepted:
08
04
2021
pubmed:
20
4
2021
medline:
27
5
2021
entrez:
19
4
2021
Statut:
ppublish
Résumé
The usefulness of bronchodilators in coronavirus diseases 2019 (COVID-19) survivors is still uncertain, especially for patients with a concomitant obstructive lung disease. We aimed at verifying the level of bronchodilator reversibility in COVID-19 patients undergoing multidisciplinary pulmonary rehabilitation after the acute phase. We enrolled 105 consecutive patients referring to the Pulmonary Rehabilitation Unit of Istituti Clinici Scientifici Maugeri Spa SB, IRCCS of Telese Terme, Benevento, Italy after being discharged from the COVID-19 acute care ward and after recovering from acute COVID-19 pneumonia. All subjects performed a spirometry before and after inhalation of salbutamol 400 μg to determine the bronchodilation response within 48 h of admission to the unit. All patients had suffered from a moderate to severe COVID-19, classified 3 or 4 according to the WHO classification, Seventeen patients had concomitant obstructive lung disease (14 suffering from COPD and 3 from asthma). FEV This study suggests that a treatment with bronchodilators must always be taken into consideration in post-COVID-19 patients because it can induce a functional improvement that, even if small, can facilitate the breathing of these patients.
Sections du résumé
BACKGROUND
The usefulness of bronchodilators in coronavirus diseases 2019 (COVID-19) survivors is still uncertain, especially for patients with a concomitant obstructive lung disease. We aimed at verifying the level of bronchodilator reversibility in COVID-19 patients undergoing multidisciplinary pulmonary rehabilitation after the acute phase.
METHODS
We enrolled 105 consecutive patients referring to the Pulmonary Rehabilitation Unit of Istituti Clinici Scientifici Maugeri Spa SB, IRCCS of Telese Terme, Benevento, Italy after being discharged from the COVID-19 acute care ward and after recovering from acute COVID-19 pneumonia. All subjects performed a spirometry before and after inhalation of salbutamol 400 μg to determine the bronchodilation response within 48 h of admission to the unit.
RESULTS
All patients had suffered from a moderate to severe COVID-19, classified 3 or 4 according to the WHO classification, Seventeen patients had concomitant obstructive lung disease (14 suffering from COPD and 3 from asthma). FEV
CONCLUSIONS
This study suggests that a treatment with bronchodilators must always be taken into consideration in post-COVID-19 patients because it can induce a functional improvement that, even if small, can facilitate the breathing of these patients.
Identifiants
pubmed: 33873099
pii: S0954-6111(21)00107-4
doi: 10.1016/j.rmed.2021.106401
pmc: PMC8041746
pii:
doi:
Substances chimiques
Bronchodilator Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106401Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Arch Bronconeumol. 2017 May;53(5):263-269
pubmed: 28292522
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
BMC Pulm Med. 2016 Nov 3;16(1):137
pubmed: 27809901
Respir Med. 2011 Mar;105(3):386-91
pubmed: 20951017
Respir Med. 2007 Aug;101(8):1798-803
pubmed: 17399972
Occup Med (Lond). 2021 Nov 6;71(8):325-327
pubmed: 33479724
Ann Am Thorac Soc. 2019 Dec;16(12):1504-1517
pubmed: 31404502
J Infect. 2021 Apr;82(4):e31-e33
pubmed: 33373650
Chest. 2011 Apr;139(4):878-886
pubmed: 20724741
Infection. 2021 Feb;49(1):153-157
pubmed: 32725597
J Thorac Imaging. 2020 Jul;35(4):W87-W89
pubmed: 32404798
Respir Care. 2012 Oct;57(10):1564-70
pubmed: 22417788
Pulmonology. 2021 Sep-Oct;27(5):452-455
pubmed: 33454281
J Clin Med. 2021 Mar 02;10(5):
pubmed: 33801455
Chest. 2011 Oct;140(4):1055-1063
pubmed: 21972384
Eur Respir J. 2020 Jun 18;55(6):
pubmed: 32381497
Thorax. 2012 Aug;67(8):701-8
pubmed: 22696176
Respirology. 2013 Nov;18(8):1223-9
pubmed: 23701193
Thorax. 2012 Aug;67(8):718-26
pubmed: 22544896
Chest. 2008 Aug;134(2):387-393
pubmed: 18403671
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Int J Clin Exp Med. 2015 Jun 15;8(6):8617-25
pubmed: 26309513
Lancet Respir Med. 2013 Sep;1(7):564-73
pubmed: 24461617
Mech Ageing Dev. 2008 Nov;129(11):625-31
pubmed: 18755207
Respir Med. 2021 Jan;176:106276
pubmed: 33278758
Biomed Res Int. 2013;2013:498205
pubmed: 24024196
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Eur Respir J. 2020 Jul 23;56(1):
pubmed: 32703822
Pulmonology. 2021 Jul-Aug;27(4):328-337
pubmed: 33262076
Respir Med. 2015 Aug;109(8):1058-62
pubmed: 26140806